Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Request Budget of ¥29,588.2 Bil., Special Framework Budget of ¥105.9 Bil. for FY2012
September 29, 2011
- CSIMC’s Committee to Assess Premium for New Drug Development Based on Results of Market Price Survey
September 29, 2011
- Record Number of New AIDS Cases Reported in 2nd Qtr. of 2011
September 28, 2011
- MHLW Approves 18 New Products
September 27, 2011
- MHLW Asks Prefectural Authorities for Cooperation to Ensure Stable Supply of Flu Vaccine
September 27, 2011
- MHLW Announces JAN for 8 Drug Candidates
September 26, 2011
- Prime Minister Noda Stresses Need for Comprehensive Reform in First Major Policy Speech
September 26, 2011
- METI Seeks Budget to Collect Cancer Tissues, Genetic Data in Fukushima
September 26, 2011
- Korosho Plans to Apply for PIC/S Membership in Early 2012
September 26, 2011
- Daiichi Sankyo Announces Approval of Silodosin in China; Aims for Launch in 2012
September 26, 2011
- Growth in Prescriptions of Prazaxa May Hit Snag Due to “Blue Letter”
September 26, 2011
- Why Generics’ Market Share Appears So Low in Japan; 20% Actually Means 35.7% if Overseas Calculation Method is Used
September 26, 2011
- 6 APIs/10 Products Including EpiPen Added to NHI Price List
September 22, 2011
- Government Designates Fulvestrant as Ad-restricted Drug
September 21, 2011
- HSC Subcommittee Agrees on Need for New System to Promote Access to Unapproved Drugs
September 20, 2011
- Price Settlement Rate Down to 73.9% of Sales in June, Close to Pre-emergency Recommendation Levels
September 19, 2011
- New METI Minister Edano Considers Drug Industry as “Highly Promising Area”
September 19, 2011
- FY2011 White Paper Calls For Reform toward “Participatory” Social Security System
September 19, 2011
- PMDA Expresses Distrust of MSD for Deviations from GCP in Trials of Gardasil
September 19, 2011
- Some Medical Institutions Still Demanding Full Payment, No Refund of Clinical Trial Costs
September 19, 2011
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…